Official facilitator of

the main

PTEN status predicts the results of prostate cancer

October 16, 2018 12:27

Loss of PTEN tumors by immunohistochemistry (IHC) of predicting prostate cancer after radical prostatectomy.

For information on how to carry out the treatment of prostate cancer in Israel, the best specialists of the country, leave a request and we will contact you shortly.

It has been shown that the status of expression of several genes involved in the pathogenesis of the prostate, the risk of stratification increases as compared with conventional clinical parameters. There have been several comparative studies between two clinical approaches used to assess the genetic characteristics of the prostate tissue (commercial assays of gene panels tumor RNA and staining of tumor tissue).

Dr. Michael S. Lepman Yale University School of Medicine, New Haven, Connecticut, and his colleagues compared the predictive utility of commercial test for expression of genes studied group of genes of cell cycle progression (MSC) compared with expression by immunohistochemistry of tumor status three changes in genomic markers prostate cancer (PTEN, ERG and Ki-67).

They studied 424 men with clinically localized prostate cancer who were treated with radical prostatectomy.

The median PCC was -0.33 and IHC showed loss of PTEN in 19% of patients, a high Ki-67 expression level and 52% positive expression of ERG in 42% (with 5% showed all three) command statements in European Urology online on 1 September.

Loss of PTEN were linked to 5.20-fold increased risk of metastasis / mortality from prostate cancer, whereas overexpression of Ki-67 positivity and ERG were not significantly associated with the main result.

Evaluation was significantly MSC is connected both to biochemical recurrence and metastatic / mortality from prostate cancer.

After adjusting to assess prostate cancer risk assessment (CAPRA-S), PTEN loss remained independently metastases / mortality from prostate cancer.

C index for predicting the risk of metastasis / mortality from prostate cancer was almost the same for a model consisting of PTEN status and CAPRA-S (0,80), and models with the progression of the cell cycle and CAPRA-S (0, 81).

"These data suggest that PTEN status integration with clinical information will represent a potentially valuable approach to improve risk assessment with a relatively small financial costs or the need for external processing" - the researchers conclude.

Dr. Eric A. Klein of the Cleveland Clinic in Cleveland, Ohio, recently discovered that the rate of 17 genes may predict prostate cancer results are better than the status of PTEN.

"It depends on what the test is looking and I would not generalize that all genomic tests are no better than the immunohistochemistry of tumors", - said Dr. Klein. "Obviously, some are better, and for each test, you must decide in each particular case."

Source: https://www.medscape.com/viewarticle/903272

APPLICATION FOR TREATMENT

The form Submitting the this by you agree to the privacy policy

Comments

No comments yet

new comment

necessarily

definitely (will not be published)